Drugs / LY4256984
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07571174 | May 2026 → Jun 2029 expected | amyotrophic lateral sclerosis | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 1 | NCT07571200 | May 2026 → Jun 2029 expected | amyotrophic lateral sclerosis | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 1 | NCT07100119 | Aug 2025 → Aug 2027 expected | amyotrophic lateral sclerosis | Eli Lilly and Company | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY4256984 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07100119 ↗ |
| Route | Intrathecal | “The study drug will be administered intrathecally (IT) into the spine.” NCT07100119 ↗ |